Cogent Biosciences, Inc. COGT
32.31
0.88
2.80%
as of 25 Sep
- Market cap
- $5.5B
- P/E
- 0.0×
Follow COGT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
6.28 | 14.08 | 14.94 | 13.36 | |
Current Ratio |
6.38 | 14.23 | 15.14 | 13.57 | |
Net Debt/EBITDA |
4.20 | 6.80 | 6.19 | 5.55 | |
Debt/Assets |
10.39% | 23.77% | 24.71% | 26.78% | |
Debt/Equity |
0.15 | 0.35 | 0.37 | 0.42 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 0.77 | 0.89 | 0.80 | |
Capex/Depreciation |
(0.08) | 4.27 | 1.63 | (5.78) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.47) | (0.61) | (0.54) | (0.45) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.47) | (0.62) | (0.54) | (0.45) | |
Cash per Share |
2.84 | 6.99 | 5.34 | 4.63 | |
Shareholders Equity per Share |
2.20 | 4.94 | 3.75 | 3.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.20 | 4.94 | 3.75 | 3.11 | |
Free Cash Flow |
(64.35) | (79.92) | (87.33) | (77.64) | |
Working Capital |
335.00 | 846.40 | 819.82 | 745.52 | |
Capital Expenditures |
(0.06) | (0.81) | (0.45) | (0.37) | |
Net Current Asset Value |
273.78 | 609.12 | 582.49 | 502.66 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
15.55 | 10.76 | 13.95 | 12.06 | |
Average Assets |
404.97 | 632.75 | 593.40 | 554.68 | |
Average Common Equity |
199.30 | 346.33 | 326.89 | 257.38 |
Columns are period end dates